Perimenopause: the transition, not the destination

Menopause is a single day. It is the 12-month anniversary of your final period. Everything before that, going back up to a decade, is perimenopause. This is the window when your ovaries get erratic before they eventually wind down.

Doctors and researchers use a reference framework called STRAW+10 (the international staging system for reproductive aging) ^[1]. It splits the window into two phases. "Early menopause transition" means the length of your cycles keeps differing by 7 or more days from one cycle to the next. "Late menopause transition" means you skip cycles, with gaps of 60 or more days. Postmenopause begins one year after your last period and lasts the rest of your life.

Stage	What it means	How you notice it
Late reproductive (premenopause)	Cycles still regular	Flow or cycle length shifts a little
Early perimenopause	Cycle length keeps varying by 7+ days [1]	First hot flashes, sleep changes
Late perimenopause	Gaps of 60+ days between periods [1]	Hot flashes likely
Menopause	One date: 12 months after your last period	Known only looking back
Postmenopause	Everything after that date	Hot flashes most common in the first years, often longer [1, 5]

In everyday speech, 'premenopause' is often used loosely for the years before menopause, sometimes as a synonym for perimenopause. Strictly, it is the phase before that, while your cycles are still regular.

Most women notice the first changes in their mid to late 40s. In the Massachusetts Women's Health Study, the median start was 47.5 and the transition lasted about 4 years on average ^[14]. A meaningful minority start earlier or take much longer. The SWAN cohort, the longest study to track the transition in a multi-ethnic US sample, found that frequent hot flashes lasted a median of 7.4 years. They kept going for a median of 4.5 years after the final period (Avis, JAMA Internal Medicine 2015) ^[5]. So the popular image of menopause as a brief inconvenience is not what the data show. It is closer to a life chapter than a season.

Three framings to drop early. Perimenopause is not a disease. It is not a deficiency. And it is not a one-symptom syndrome. It is a normal endocrine transition, often a demanding one, and the experience varies wildly. Some women barely notice. Roughly a quarter report symptoms bad enough to interfere with work or relationships. Both are normal. Knowing where you sit in the staging matters, because the same symptom can mean different things at 43 with regular periods than at 51 after a year of skipped ones.

The most common perimenopause symptoms are hot flashes and night sweats (vasomotor symptoms, affecting up to about 80% of women), disrupted sleep, mood and anxiety changes, mild reversible 'brain fog', urogenital dryness, and joint aches. To map your symptoms systematically, try our menopause symptom checker. It is a whole-body transition, not a single-symptom syndrome, and the mix varies between women and over time.

Hot flashes and night sweats are the best known. Severity ranges from background warmth to drenching night sweats that wreck your sleep for years. Sleep itself is its own beast. That hot flashes disrupt sleep is backed by the SWAN cohort and by experiments from Joffe and colleagues. Joffe's team used a GnRH agonist (a drug that temporarily shuts down the ovaries' hormone output) to trigger the hormonal shift on purpose in healthy premenopausal volunteers. The result points to a causal link: objectively measured hot flashes worsen sleep efficiency (the share of time in bed you actually spend asleep) ^[18]. But plenty of women also develop insomnia that has nothing to do with night sweats. Early waking. Racing-mind nights. Lighter sleep. The two problems then compound each other.

Mood and cognition deserve careful framing. Perimenopause raises the risk of new depression and anxiety, even in women with no prior history. This is biology, not weakness, and it warrants real attention rather than self-diagnosis. If mood symptoms feel out of proportion to your circumstances, or they last for weeks, talk to your GP or a Hausärztin or Frauenärztin. Do not wait.

On cognition: SWAN's long-term data (Greendale, Neurology 2009) found a measurable but reversible dip in processing speed and verbal memory during the transition. It recovers in early postmenopause ^[6]. So the "brain fog" is real, and it is usually not the start of dementia.

Urogenital changes are badly under-discussed. Vaginal dryness, recurrent UTIs, urinary urgency, and discomfort during sex are all common. They often show up late in the transition, and unlike hot flashes they do not resolve on their own. Round out the picture with joint aches (the so-called "menopause joint"), heart palpitations, shifting migraine patterns, weight moving toward the midsection, and changes in skin and hair. None of these are imagined. None of them are diagnostic on their own.

The defining hormonal feature of early perimenopause is volatility, not steady decline: estradiol can spike above premenopausal levels in one cycle and crash in the next, while FSH rises erratically. Cardiometabolic risk shifts unfavourably, bone loss accelerates, and the brain reorganises under changing hormones.

The popular story is that estrogen "drops." For perimenopause, that is misleading. The defining feature of the early transition is volatility, not depletion. Estradiol can spike well above premenopausal levels in some cycles, then crash in others. FSH (follicle-stimulating hormone, the signal your brain sends to your ovaries) rises as the brain shouts louder at ovaries that respond less and less. But FSH is erratic in early perimenopause too. That is why a single blood test on a random cycle day is almost meaningless for diagnosis in your 40s. At this stage, diagnosis is clinical: based on your cycle changes and your symptoms.

Your heart and metabolism shift in ways that stack on top of normal aging. The SWAN heart study and others document faster visceral fat gain, a less friendly lipid profile (LDL cholesterol and apoB jump around the final period ^[16]; HDL cholesterol actually rises, but the particles seem to protect less well ^[15]), and a measurable bump in cardiovascular risk markers across the transition. Some of that happens independent of weight change.

Bone loss speeds up too. In SWAN, bone density at the spine and hip started dropping about one year before the final period and fell fastest until two years after it. About 7 percent of spine density went in that window alone ^[17]. That is one reason it pays to check your fracture risk early. Loading and weight-bearing exercise pay off most right now, not after an osteoporosis diagnosis.

The brain adapts as well. A 2021 multi-modality neuroimaging study (Mosconi, Scientific Reports 2021) compared pre-, peri-, and postmenopausal women. It found stage-related differences in brain structure, connectivity, and energy metabolism, with grey-matter volume and some metabolic measures looking more favourable in postmenopause than in perimenopause ^[8]. The study is cross-sectional, so "recovery" is inferred from differences between groups, not tracked within the same women over time. That makes it a plausible brain-level explanation for brain fog, not a proven one. None of it means the brain is breaking. It means the brain is reorganising under different hormonal conditions.

The lifestyle anchors with real trial support are progressive strength training (2 to 3 sessions a week), adequate protein at 1.2 to 1.6 g/kg, CBT-I for insomnia, and a Mediterranean-style diet. Less alcohol helps your sleep. Supplement stacks and "natural HRT" claims do not have that kind of support.

Strength training is the single highest-payoff lifestyle move for this life stage. The LIFTMOR trial tested it in postmenopausal women with low bone mass, a group previously told to avoid heavy loading (Watson, Journal of Bone and Mineral Research 2018) ^[7]. High-intensity progressive resistance and impact training improved bone mineral density at the spine and the femoral neck (the top of the thigh bone, just below the hip joint). The trial did not include perimenopausal women. The principle plausibly carries over, but nobody has trialled it there yet. Muscle is also the largest glucose sink in your body, which directly counters the metabolic drift of the transition. The prescription: two to three structured sessions a week, with progressive loading. Our exercise for longevity guide covers how to structure those sessions.

Sleep hygiene becomes non-optional, but be realistic. When night sweats are the driver, behavioural sleep tweaks alone only go so far. Cooling the bedroom (16-18°C), moisture-wicking sleepwear, and a consistent wake time all help. For chronic insomnia in this group, CBT-I (cognitive behavioural therapy for insomnia, the structured talking-therapy protocol for long-term sleep problems) has the strongest evidence base. In Germany, it is reimbursable through statutory health insurance (gesetzliche Krankenkasse). For the broader sleep playbook, see our sleep and longevity guide.

Now diet, where the evidence is messier than wellness marketing would have you believe. A Mediterranean-style way of eating is linked to better heart and metabolic outcomes broadly, midlife women included. Claims for specific "menopause diets" or phytoestrogen-heavy protocols rest mostly on observational and short-term trial data. Useful, not definitive. Adequate protein (roughly 1.2-1.6 g/kg body weight) supports muscle retention alongside strength training. Alcohol reliably fragments sleep. Some women also find it sets off their flashes, but studies on alcohol and hot flashes are mixed ^[19], so treat it as a personal trigger to test, not a rule.

Stress regulation is real physiology here, not just a wellness add-on. Your HPA axis (the hypothalamus-pituitary-adrenal stress system) and the sex steroid axes are tangled together, and unmanaged chronic stress amplifies symptoms. For stress, anything backed by randomised controlled trials (RCTs) is reasonable: mindfulness-based stress reduction, yoga, structured aerobic exercise. For the hot flashes themselves, CBT and clinical hypnosis have the stronger trial evidence ^[13]. What does not have strong evidence: supplement stacks marketed for menopause, "cortisol detoxes," and bioidentical compounded preparations sold outside clinical channels.

Current guidelines (NICE NG23, NAMS 2022, DGGG S3) agree that for healthy women under 60, or within 10 years of menopause, with bothersome vasomotor symptoms, the benefit-risk profile of hormone therapy (HRT/MHT) is generally favourable ^{[4, 10, 11]}. A flat "HRT is dangerous" position is not where the evidence sits in 2026, but the decision is individual and belongs in a consultation.

This is the topic where the public conversation has done the most damage, and it is now slowly course-correcting. The headline: hormone therapy (HRT in the UK, MHT or menopausal hormone therapy in current international usage) is back in the mainstream conversation for women with symptoms. But the decision is individual, and it belongs in a consultation with your Frauenärztin, Gynäkologin, or Wahlärztin (in Austria), not on the internet. For the full protocol-level read on HRT and TRT in DACH, see our companion guide on Hormonersatztherapie & TRT.

Three references matter in 2026:

• NICE NG23 (UK; substantive update November 2024, last amended April 2026) ^[11]
• The NAMS 2022 Hormone Therapy Position Statement ^[4] (NAMS is now called The Menopause Society)
• The DGGG/OEGGG S3 Leitlinie Peri- und Postmenopause (AWMF 015-062, the 2020 version with a September 2020 addendum) ^[10]

One caveat on that last one. Its AWMF validity expired at the end of 2024, the guideline has been officially under revision (in Überarbeitung) since 2025, and the updated version is expected through 2026. So when a DACH clinician quotes the S3, ask whether they mean the 2020 text or the upcoming revision. All three guidelines land on similar core principles, even where the dosing and product details differ.

Regulators are moving too. In November 2025 the US FDA began removing the broad boxed warnings on cardiovascular disease, breast cancer and probable dementia from hormone therapy labels ^[12]. The one it kept is the endometrial cancer warning for systemic estrogen alone. That is why anyone with a uterus needs a progestogen alongside estrogen. European labels are set separately by the EMA and national agencies.

So why did the verdict change? The scary harm signals from the original Women's Health Initiative (WHI) reports were partly an artefact of an older study population (mean age 63), and later re-analyses have reframed them. The 18-year follow-up of the WHI (Manson, JAMA 2017) found no significant difference in all-cause mortality between women randomised to hormone therapy and women on placebo ^[2]. The ELITE trial (Hodis, NEJM 2016) directly tested the "timing hypothesis": does it matter when you start? Estradiol slowed the progression of subclinical atherosclerosis (artery-wall thickening visible on ultrasound before any symptoms) only in women who started within six years of menopause, not later ^[3]. One caveat: that is a surrogate measure, an early warning marker, not actual heart attacks or strokes.

Breast cancer risk depends on the formulation and how long you take it. In WHI long-term follow-up (Chlebowski, JAMA 2020), the rise in breast cancer cases was concentrated in the combined estrogen + progestin arm (CEE + MPA) ^[9]. The estrogen-alone arm (CEE in women after hysterectomy) showed no comparable rise. On extended follow-up it actually showed a significant reduction in both breast cancer incidence and breast cancer mortality. So a flat "HRT raises breast cancer" summary over-simplifies.

What this does not mean. It does not mean MHT is risk-free. It does not mean every woman should be on it. And it does not mean compounded "bioidentical" preparations are safer than regulated products. They are not, and major guidelines specifically caution against unregulated compounded formulations. Your individual breast cancer risk, your cardiovascular history, your migraine pattern, the type of progestogen used, and the route of administration all matter. The conversation deserves a real consultation rather than a default no.

Here is how the main treatment options compare:

Option	Mainly helps with	Note
Systemic HRT/MHT	Hot flashes, sleep, bone	Benefit-risk generally favourable under 60 or within 10 years of menopause [4, 11]
Vaginal estrogen	Dryness, recurrent UTIs, painful sex	Works locally at a very low dose [11]
Fezolinetant (Veoza), elinzanetant (Lynkuet)	Hot flashes, night sweats	Non-hormonal neurokinin blockers (fezolinetant blocks NK3, elinzanetant NK1 and NK3), EU-approved 2023 and 2025. Fezolinetant needs liver blood tests [13, 22, 23]
SSRIs/SNRIs, gabapentin	Hot flashes	Options when hormones are not suitable [13]
CBT, clinical hypnosis	Hot flashes; CBT also helps sleep and mood	Good trial evidence, no drugs involved [11, 13]
Strength training	Bone, muscle, metabolism	See the lifestyle section above [7]

There is no perimenopause panel that your Krankenkasse reimburses as a screening package. What gets covered depends on what is investigated and why. Here is a practical approach.

When there is a clinical reason, the gesetzliche Krankenkasse (GKV, statutory health insurance) generally covers:

• a gynaecological exam
• basic blood work: TSH (thyroid), ferritin (iron stores), full blood count, lipids, and HbA1c (long-term blood sugar) when risk factors are present
• a bone density scan (DEXA, or Knochendichtemessung) when it is clinically indicated, regardless of age. Typical reasons: a fragility fracture (a break from a fall that should not break a healthy bone) plus suspected osteoporosis, or starting or monitoring a specific osteoporosis therapy.

Routine DEXA screening of women without symptoms or risk factors is not covered. It lands in IGeL/Selbstzahler (self-pay) territory. (The age-65 cutoff you may have read about is the US USPSTF screening standard, not the German rule.)

Private or IGeL pricing usually applies to "menopause panels" with estradiol, FSH, LH, AMH, and progesterone, to cardiometabolic panels beyond standard lipids, and to elective DEXA for baseline tracking. Hormone testing is also strongly cycle-day-dependent. A randomly timed estradiol in early perimenopause can read almost anything. So insist that any hormone panel comes with a specific cycle-day rationale. Without one, it is basically a vanity test. In Austria, the Wahlärztin pathway gives you longer appointments and easier access to extended panels, with partial reimbursement through the e-card system afterward.

Mental health screening matters, and it routinely gets left out. A validated questionnaire (PHQ-9 for depression, GAD-7 for anxiety) takes five minutes and is the right baseline at this life stage. If it flags anything, GKV-covered psychotherapy referral exists in Germany, though the waiting lists are long.

So what does a sensible minimum baseline look like for most women entering or in perimenopause? Blood pressure, a lipid panel, HbA1c, TSH, ferritin, vitamin D (if not measured in the last two years), and at least one validated mental-health questionnaire. A baseline DEXA as an IGeL is reasonable to consider if there is a family history of osteoporosis or any fragility-fracture history. And cycle tracking (a notebook or an app) is a high-value self-knowledge tool, not a diagnostic.